Financials in USD. Standardized financial statements.
A compact view of how Omada Health turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue? | $260.21M | $169.80M | $122.78M | $89.19M |
| Revenue Growth? | +53.2% | +38.3% | +37.7% | 0.0% |
| Cost of Revenue? | $89.27M | $66.92M | $52.81M | $46.39M |
| Gross Profit? | $170.94M | $102.88M | $69.97M | $42.79M |
| Gross Margin? | +65.7% | +60.6% | +57.0% | +48.0% |
| Operating Expenses? | $182.91M | $146.53M | $135.97M | $115.14M |
| Operating Income? | -$11.97M | -$43.65M | -$66.00M | -$72.35M |
| EBITDA? | -$4.75M | -$37.83M | -$58.36M | -$63.99M |
| Income Before Tax | -$12.78M | -$47.14M | -$67.51M | -$72.52M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income? | -$12.78M | -$47.14M | -$67.51M | -$72.52M |
| EPS? | $-0.22 | $-0.85 | $-1.21 | $-1.30 |
| Diluted EPS? | $-0.22 | $-0.85 | $-1.21 | $-1.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality